Customer Service: 866-788-9007

Customer Service: 866-788-9007

Customer Service: 866-788-9007

Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology.  We continue to focus our resources on the development and marketing of our DecisionDx molecular diagnostic tests that have the ability to meaningfully impact how dermatologic cancers are diagnosed and managed.

  • Jun 23, 2019

    Began operations

    2008

  • Jun 19, 2019

    Introduction of DecisionDx®-UM

    2009

  • Jun 19, 2019

    DecisionDx-UM included in AJCC guidelines

    2010

  • Publication of Prospective DecisionDx-UM Validation Study (COOG)

    2012

  • Introduction of DecisionDx®-Melanoma

    2013

  • Introduction of DecisionDx®-PRAME

    2016

  • Jun 13, 2019

    Phoenix laboratory expansion completed

    2016

  • Jun 13, 2019

    Formal Medicare LCD coverage for DecisionDx-UM

    2017

  • Jun 13, 2019

    DecisionDx-UM included in NCCN guidelines

    2018

  • Jun 13, 2019

    Formal Medicare LCD coverage for DecisionDx-Melanoma

    2018

  • Jun 13, 2019

    Introduction of DecisionDx®-CMSeq

    2018

  • Jun 13, 2019

    Introduction of DecisionDx®-UMSeq

    2018

  • Jun 13, 2019

    First DecisionDx®-SCC data presented

    2018

  • Jun 13, 2019

    Initial public offering completed

    2019

  • Jun 13, 2019

    First two meta-analyses published for DecisionDx-Melanoma

    2020

  • Jun 13, 2019

    Introduction of DecisionDx-SCC

    2020

Castle Biosciences has consistently applied emerging techniques in molecular diagnostics to improve patient care and outcomes.

  • For more information on DecisionDx-Melanoma